Read more

July 05, 2024
2 min read
Save

GLP-1s tied to lower risk for 10 types of cancer compared with insulin in type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • People with type 2 diabetes using a GLP-1 medication have a lower risk for most obesity-associated cancers than insulin users.
  • The risk for most types of cancer was similar between GLP-1 and metformin users.
Perspective from Emily Gallagher, MD, PHD

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

“This study adds to the growing body of evidence supporting the pleiotropic effects of GLP-1 receptor agonists on cancer prevention,” Lindsey Wang, an undergraduate student in the pre-professional scholars program at Case Western Reserve University, told Healio. “For patients with type 2 diabetes, particularly those with obesity, GLP-1 receptor agonists may offer protective benefits against specific cancers. Clinicians might consider preferring GLP-1 receptor agonists over other diabetes treatments, such as insulin, for patients at high risk of obesity-associated cancers.”

Risk for 10 types of cancer lower for GLP-1 users than insulin users
Infographic content were derived from Wang L, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.21305.

Wang and colleagues conducted a retrospective cohort study of deidentified electronic health records on the TriNetX platform. People with type 2 diabetes who were prescribed a GLP-1 receptor agonist, insulin or metformin and had no history of an obesity-associated cancer from March 2005 to November 2018 were included (mean age, 59.8 years; 50.1% men). Researchers collected diagnoses of 13 types of obesity-associated cancer. Two analyses were conducted using propensity-score matching for baseline covariates. People using a GLP-1 and no insulin were matched, 1:1, with those using insulin and no GLP-1 in the first analysis. The second analysis matched people using a GLP-1 and no metformin, 1:1, with those using metformin and no GLP-1.

Co-authors Lindsey Wang and Nathan Berger, MD. Source: Lindsey Wang

Compared with those using insulin, people using a GLP-1 receptor agonist had a lower risk for developing gallbladder cancer (HR = 0.35; 95% CI, 0.15-0.83), meningioma (HR = 0.37; 95% CI, 0.18-0.74), pancreatic cancer (HR = 0.41; 95% CI, 0.33-0.5), hepatocellular carcinoma (HR = 0.47; 95% CI, 0.36-0.61), ovarian cancer (HR = 0.52; 95% CI, 0.03-0.74), colorectal cancer (HR = 0.54; 95% CI, 0.46-0.64), multiple myeloma (HR = 0.59; 95% CI, 0.44-0.77), esophageal cancer (HR = 0.6; 95% CI, 0.42-0.86), endometrial cancer (HR = 0.74; 95% CI, 0.6-0.91) and kidney cancer (HR = 0.76; 95% CI, 0.64-0.91). No difference in stomach cancer, postmenopausal breast cancer or thyroid cancer risk was seen between the two groups.

“One particularly noteworthy association that stood out is the significant risk reduction across multiple gastrointestinal cancers, including colorectal, esophageal, stomach, gallbladder, liver and pancreatic cancers,” Wang said. “This is especially important given the often poor prognosis of these cancers. Surprisingly, no associations were found between GLP-1 receptor agonists and breast cancer risk.”

People prescribed GLP-1s had a higher risk for kidney cancer compared with those receiving metformin (HR = 1.54; 95% CI, 1.27-1.87). No difference in risk between the two groups was observed for any other obesity-associated cancer.

Wang said several types of studies are needed to further explore the link between GLP-1s and obesity-associated cancers.

“Prospective randomized clinical trials are essential to confirm these associations and establish causality,” Wang said. “Preclinical studies are needed to elucidate the underlying mechanisms. Additionally, research to examine the newer and more potent weight-loss GLP-1 receptor agonists, semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly), would be particularly important.”